MRI-based technologies for assessing non-alcoholic fatty liver disease: diagnostics consultation
We are listening to your views on this Diagnostics guidance. Comments close 14 July 2022.
Search results
10 results
-
-
GID-MT564 GreenLight XPS for treating benign prostatic hyperplasia: draft guidance
We are listening to your views on this Medical technologies guidance. Comments close 13 July 2022.
-
GID-MT565 Optilume for recurrent bulbar urethral strictures: draft guidance
We are listening to your views on this Medical technologies guidance. Comments close 12 July 2022.
-
Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223
Awaiting development [GID-HST10019] Expected publication date: TBC
-
Leriglitazone for treating andrenoleukodystrophy [ID3903]
Awaiting development [GID-HST10049] Expected publication date: TBC
-
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]
Awaiting development [GID-HST10022] Expected publication date: TBC
-
Lonafarnib for treating progeria and progeroid laminopathies [ID3867]
Awaiting development [GID-HST10039] Expected publication date: TBC
-
VTS-270 for treating Niemann-Pick type C1 (ID1267)
Awaiting development [GID-HST10020] Expected publication date: TBC
-
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]
Awaiting development [GID-HST10032] Expected publication date: TBC
-
Asfotase alfa for treating paediatric-onset hypophosphatasia (review of HST6) [ID3927]
Awaiting development [GID-HST10046] Expected publication date: 15 December 2022